LONDON, September 4, 2012 /PRNewswire/ --
Pharma IQ recently launched its 2012 Pharmaceutical Co-Crystals and Amorphous Materials Summit programmes, featuring a brand new Solid Form Co-Crystals and Amorphous Focus Morning. This Focus Morning is aim to discovery the overlapping and discuss crucial areas that are involved in both, as well as to give participants as much input and expertise from across both areas in one space.
The Solid Form Co-Crystals and Amorphous Focus Morning features case studies and interactive sessions on the effective characterisation of co-crystals and amorphous. From the discriminatory analysis on dissolution behaviour of several disordered/amorphous forms to amorphous fractions in crystalline materials. These topics will help participants to understand structure and dynamics in pharmaceutical solids.
Four professors from UK's leading labs will lead roundtable discussions which will cover pressing questions about the future application of co-crystals and amorphous techniques both in pharmaceuticals and outside, the latest developments affecting bioavailability and the FDA policy of solid form.
In addition to the Focus Morning, the 2012 summit programme will assess the clinical application of co-crystals and amorphous forms into the manufacturing scale up process, focus on developing and forming effective co-crystals and amorphous designs throughout the phases of development and utilise novel methods of formulation identification to improve drug efficacy, reduce cost of development and expedite time to market.
With the release of the new FDA draft guidance on classification of solid form and the regulatory implications of this classification, it is crucial to learn the newest and most innovative developments in characterisation, predictability, processing as well as the legal and regulatory challenges.
Taking place from 25th to 26th September, Pharmaceutical Co-Crystals and Am